Managing Cutaneous Toxicity in Oncological Treatments



Addressing and Alleviating Skin Reactions

Effectively managing cases of cutaneous toxicity is essential not only to improve the quality of life of oncology patients but also to prevent the discontinuation of cancer therapies.

Many pharmacological agents commonly used in cancer treatment are associated with cutaneous toxicity as a side effect. In some patients, skin reactions may occur as early as four weeks after the initial administration, while in others, they may manifest up to a year into treatment.

Currently, the recommended therapeutic strategies include the use of corticosteroids and anti-inflammatory treatments.

In this context, the anti-inflammatory and immunomodulatory effects of omega-3 essential fatty acids may offer additional benefits. Alpha-linolenic acid, for instance, is incorporated into cell membranes and acts by reducing the synthesis of pro-inflammatory metabolites, while promoting the production of pro-resolving mediators of inflammation such as resolvins, protectins, and maresins.

Furthermore, the use of emollients and increased attention to the hydration of the hands and feet is strongly advised, as this can help avoid the need to reduce chemotherapy dosages or interrupt treatment altogether.

For daily hygiene, it is also recommended to use low- or non-foaming cleansers with a high percentage of vegetable oils, which are rich in fatty acids known for their significant emollient properties.